No trading action warranted. This is a routine annual meeting and director compensation update with no earnings, guidance, or operational news. Monitor next quarterly earnings for commercial progress of ZORYVE and pipeline updates.
Price Chart
Executive Summary
Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three proposals were approved, including the election of three Class III directors, ratification of Ernst & Young as independent auditor, and non-binding advisory approval of executive compensation. Separately, the Board approved an amended and restated Non-Employee Director Compensation Program, effective June 5, 2026, which sets annual cash retainers (e.g., $50,000 base for non-employee directors) and equity awards (initial option up to $350,000 grant date fair value, annual awards of ~$350,000 split 65% options / 35% RSUs). This is a routine governance filing with no material financial impact.
Key Facts
- All three proposals at the 2026 Annual Meeting were approved by stockholders.
- Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
- Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026 approved (107,867,442 for, 15,748 against, 261,364 abstentions).
- Non-binding advisory approval of named executive officer compensation passed (88,728,269 for, 3,723,408 against, 824,860 abstentions, 14,868,017 broker non-votes).
- Board approved Amended and Restated Non-Employee Director Compensation Program effective June 5, 2026.
- Annual cash retainer for non-employee directors: $50,000; additional $40,000 for Non-Executive Chair.
- Annual equity award grant date fair value approximately $350,000 per director (65% options, 35% RSUs).
- Initial option grant for new directors: up to $350,000 grant date fair value, vesting over three years.
Financial Impact
No material financial impact. Director compensation changes are routine and within standard ranges for a $2.7B market cap biotech.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-041883 |
| Exhibit: exhibit101amendedandrestat.htm | 0001628280-26-041883 |
| Document: 0001628280-26-041883-index-headers.html | 0001628280-26-041883 |
| Document: 0001628280-26-041883-index.html | 0001628280-26-041883 |
| Document: 0001628280-26-041883.txt | 0001628280-26-041883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $25.16 (+1.21%) |
Aug 21, 2026 6w ago | Insider Cluster | $25.08 $25.96 | ▲ +3.51% | ▲ +4.04% | $25.16 (+0.32%) |
Aug 19, 2026 6w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $25.16 (−0.75%) |
Aug 11, 2026 7w ago | 144 | $26.28 $23.38 | ▼ −11.04% | ▼ −9.14% | $25.16 (−4.26%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 5, 2026 8w ago | Press Release | $26.43 $23.66 | ▼ −10.48% | ▼ −11.08% | $25.16 (−4.81%) |
Aug 3, 2026 8w ago | 144 | $26.03 $23.75 | ▼ −8.76% | ▼ −7.52% | $25.16 (−3.34%) |
Jun 29, 2026 13w ago | Press Release | $26.22 $27.84 | ▲ +6.18% | ▲ +7.21% | $25.16 (−4.04%) |
Jun 18, 2026 15w ago | Insider Cluster | $26.21 $27.74 | ▲ +5.84% | ▲ +5.30% | $25.16 (−4.01%) |
Jun 9, 2026 16w ago | 8-K | $23.23 $28.78 | ▲ +23.89% | ▲ +20.27% | $25.16 (+8.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access